Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:amino acid
go back to main search page
Accession:CHEBI:33709 term browser browse the term
Definition:A carboxylic acid containing one or more amino groups.
Synonyms:related_synonym: Aminocarbonsaeure;   Aminokarbonsaeure;   Aminosaeure;   amino acids
 alt_id: CHEBI:13815;   CHEBI:22477;   MESH:D000596
 xref_mesh: MESH:D000596
 xref: Wikipedia:Amino_acid
 cyclic_relationship: is_conjugate_acid_of CHEBI:37022


show annotations for term's descendants           Sort by:
 
cilazapril monohydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen decreases expression EXP Cilazapril results in decreased expression of AGT protein CTD PMID:2419701 NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
JBrowse link
G REN renin increases activity EXP Cilazapril results in increased activity of REN protein CTD PMID:2419701 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
corticotropin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G INS insulin increases abundance EXP INS protein results in increased abundance of Adrenocorticotropic Hormone CTD PMID:1646414 NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
JBrowse link
diclofenac term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2C41 cytochrome P450 2C41 affects metabolic processing EXP CYP2C9 protein affects the metabolism of Diclofenac CTD PMID:15801540
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP Diclofenac results in decreased activity of PTGS1 protein alternative form CTD PMID:12242329 NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
JBrowse link
DPDPE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1B3 solute carrier organic anion transporter family member 1B3 increases transport EXP SLCO1B3 protein results in increased transport of Enkephalin, D-Penicillamine (2,5)- CTD PMID:20079461 NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
JBrowse link
emodepside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 affects response to substance EXP ABCB1 protein affects the susceptibility to emodepside CTD PMID:25660379 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
enalapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP2A2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 multiple interactions EXP [Ranolazine co-treated with Enalapril] affects the expression of ATP2A2 protein CTD PMID:18820026 NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
JBrowse link
G EGR1 early growth response 1 multiple interactions EXP [Ranolazine co-treated with Enalapril] affects the expression of EGR1 protein CTD PMID:18820026 NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
JBrowse link
G GATA4 GATA binding protein 4 multiple interactions EXP [Ranolazine co-treated with Enalapril] affects the expression of GATA4 protein CTD PMID:18820026 NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
JBrowse link
G KCND3 potassium voltage-gated channel subfamily D member 3 decreases expression EXP Enalapril results in decreased expression of KCND3 mRNA CTD PMID:19732978 NCBI chr17:63,470,829...63,668,354
Ensembl chr17:63,470,415...63,668,035
JBrowse link
G NAB1 NGFI-A binding protein 1 multiple interactions EXP [Ranolazine co-treated with Enalapril] affects the expression of NAB1 protein CTD PMID:18820026 NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions
increases expression
EXP FR 173657 inhibits the reaction [Enalapril results in increased expression of NOS3 mRNA] CTD PMID:12019275 NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
JBrowse link
G NPPA natriuretic peptide A decreases expression
multiple interactions
EXP Enalapril results in decreased expression of NPPA protein
FR 173657 inhibits the reaction [Enalapril results in decreased expression of NPPA protein]
CTD PMID:12019275 NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
JBrowse link
G REN renin increases activity
multiple interactions
EXP Enalapril results in increased activity of REN protein
[Enalapril co-treated with FR 173657] results in increased activity of REN protein
CTD PMID:12019275 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
G SLC8A1 solute carrier family 8 member A1 multiple interactions EXP [Ranolazine co-treated with Enalapril] affects the expression of SLC8A1 protein CTD PMID:18820026 NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
JBrowse link
flufenamic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G DHRS4 dehydrogenase/reductase 4 decreases activity EXP Flufenamic Acid results in decreased activity of DHRS4 protein CTD PMID:17827741 NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
JBrowse link
glutathione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CLDN4 claudin 4 multiple interactions EXP Glutathione inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] CTD PMID:23816505 NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein] CTD PMID:23816505 NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein] CTD PMID:23816505 NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions EXP Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] CTD PMID:23816505 NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] CTD PMID:23816505 NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
JBrowse link
mastoparan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GNAQ G protein subunit alpha q multiple interactions EXP G(M1) Ganglioside inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; mastoparan results in increased activity of and affects the localization of GNAQ protein CTD PMID:21671308 NCBI chr 1:80,733,530...80,928,065
Ensembl chr 1:80,715,366...80,928,065
JBrowse link
G HEXB hexosaminidase subunit beta multiple interactions
increases secretion
EXP G(M1) Ganglioside inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; methyl-beta-cyclodextrin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; Pertussis Toxin inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Quinacrine promotes the reaction [mastoparan results in increased secretion of HEXB protein]; YM-254890 inhibits the reaction [mastoparan results in increased secretion of HEXB protein] CTD PMID:21671308 NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
JBrowse link
melittin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HEXB hexosaminidase subunit beta multiple interactions
increases secretion
EXP G(M1) Ganglioside inhibits the reaction [Melitten results in increased secretion of HEXB protein]; sialogangliosides inhibits the reaction [Melitten results in increased secretion of HEXB protein]; trisialoganglioside GT1 inhibits the reaction [Melitten results in increased secretion of HEXB protein] CTD PMID:21334356 NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
JBrowse link
N-acetyl-L-cysteine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CLDN4 claudin 4 multiple interactions EXP Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] CTD PMID:23816505 NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein] CTD PMID:23816505 NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein] CTD PMID:23816505 NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions EXP Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] CTD PMID:23816505 NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] CTD PMID:23816505 NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
JBrowse link
nefiracetam term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PTGS2 prostaglandin-endoperoxide synthase 2 affects expression
increases expression
EXP nefiracetam affects the expression of PTGS2 mRNA
nefiracetam results in increased expression of PTGS2 protein
CTD PMID:16105799 NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
JBrowse link
ritonavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions EXP allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] CTD PMID:15266218 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases activity EXP Ritonavir results in increased activity of NR1I2 protein CTD PMID:27732639 NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
JBrowse link
saquinavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC2 ATP binding cassette subfamily C member 2 affects transport EXP ABCC2 protein affects the transport of Saquinavir CTD PMID:12702717 NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
JBrowse link
SDZ PSC 833 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions EXP valspodar inhibits the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]; valspodar inhibits the reaction [ABCB1 protein affects the susceptibility to Vincristine]; valspodar inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] CTD PMID:15492788, PMID:24975508 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
sincalide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO1B3 solute carrier organic anion transporter family member 1B3 increases transport EXP SLCO1B3 protein results in increased transport of Sincalide CTD PMID:20079461 NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
JBrowse link
Temocaprilat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC2 ATP binding cassette subfamily C member 2 affects transport EXP ABCC2 protein affects the transport of temocaprilat CTD PMID:15507541 NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
JBrowse link
tolfenamic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PTGS2 prostaglandin-endoperoxide synthase 2 decreases expression EXP tolfenamic acid results in decreased expression of PTGS2 mRNA CTD PMID:15198222 NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
JBrowse link
vasopressin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G INS insulin multiple interactions EXP INS protein promotes the reaction [Sodium results in increased abundance of Vasopressins] CTD PMID:1324617 NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 225
    role 225
      application 192
        refrigerant 68
          ammonia 68
            organic amino compound 68
              amino acid 26
                1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid + 0
                1-(4-sulfophenyl)-3-carboxy-4-amino-5-oxopyrazole 0
                2,3-dihydro-3-hydroxyanthranilic acid + 0
                2,3-dihydro-3-oxoanthranilic acid 0
                4-(aminomethyl)-1-cyclohexanecarboxylic acid 0
                5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid + 0
                7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid + 0
                8-amino-7-oxononanoic acid 0
                Cytomycin 0
                LY-221481 0
                N-[2-(4-aminophenyl)ethyl]-4-phenylisonipecotic acid + 0
                N-acyl-amino acid + 5
                N-methylleucine 0
                NNAL-N-glucuronide 0
                aceclofenac 0
                alminoprofen 0
                alpha-amino acid + 11
                amfenac + 0
                amineptine + 0
                amino dicarboxylic acid + 0
                amino fatty acid + 0
                amino-acid residue + 19
                aminooxyacetic acid 0
                aromatic amino acid + 2
                azetidine-2-carboxylic acid + 0
                branched-chain amino acid + 2
                bumetanide 0
                carboxyamino acid + 0
                diamino acid + 0
                diclofenac + 2
                dimethylcarbamic acid + 0
                enoxacin 0
                gamma-L-glutamyl-L-alpha-aminobutyrate 0
                glycine thiazolecarboxylic acid 0
                glyco-amino acid + 0
                hexylcarbamic acid 0
                lumiracoxib 0
                mediomycin A 0
                mediomycin B 0
                mesalamine 0
                methylcarbamic acid + 0
                non-proteinogenic amino acid + 3
                nonpolar amino acid 0
                oseltamivir acid 0
                phenylcarbamic acid + 0
                pipemidic acid 0
                polar amino acid + 6
                polyamino carboxylic acid + 0
                propylcarbamic acid 0
                substituted beta-amino acids 0
                sulfur-containing amino acid + 5
                trovafloxacin 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 225
    subatomic particle 225
      composite particle 225
        hadron 225
          baryon 225
            nucleon 225
              atomic nucleus 225
                atom 225
                  main group element atom 218
                    p-block element atom 218
                      carbon group element atom 207
                        carbon atom 206
                          organic molecular entity 206
                            organic group 154
                              organic divalent group 153
                                organodiyl group 153
                                  carbonyl group 153
                                    carbonyl compound 153
                                      carboxylic acid 114
                                        amino acid 26
                                          1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid + 0
                                          1-(4-sulfophenyl)-3-carboxy-4-amino-5-oxopyrazole 0
                                          2,3-dihydro-3-hydroxyanthranilic acid + 0
                                          2,3-dihydro-3-oxoanthranilic acid 0
                                          4-(aminomethyl)-1-cyclohexanecarboxylic acid 0
                                          5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid + 0
                                          7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid + 0
                                          8-amino-7-oxononanoic acid 0
                                          Cytomycin 0
                                          LY-221481 0
                                          N-[2-(4-aminophenyl)ethyl]-4-phenylisonipecotic acid + 0
                                          N-acyl-amino acid + 5
                                          N-methylleucine 0
                                          NNAL-N-glucuronide 0
                                          aceclofenac 0
                                          alminoprofen 0
                                          alpha-amino acid + 11
                                          amfenac + 0
                                          amineptine + 0
                                          amino dicarboxylic acid + 0
                                          amino fatty acid + 0
                                          amino-acid residue + 19
                                          aminooxyacetic acid 0
                                          aromatic amino acid + 2
                                          azetidine-2-carboxylic acid + 0
                                          branched-chain amino acid + 2
                                          bumetanide 0
                                          carboxyamino acid + 0
                                          diamino acid + 0
                                          diclofenac + 2
                                          dimethylcarbamic acid + 0
                                          enoxacin 0
                                          gamma-L-glutamyl-L-alpha-aminobutyrate 0
                                          glycine thiazolecarboxylic acid 0
                                          glyco-amino acid + 0
                                          hexylcarbamic acid 0
                                          lumiracoxib 0
                                          mediomycin A 0
                                          mediomycin B 0
                                          mesalamine 0
                                          methylcarbamic acid + 0
                                          non-proteinogenic amino acid + 3
                                          nonpolar amino acid 0
                                          oseltamivir acid 0
                                          phenylcarbamic acid + 0
                                          pipemidic acid 0
                                          polar amino acid + 6
                                          polyamino carboxylic acid + 0
                                          propylcarbamic acid 0
                                          substituted beta-amino acids 0
                                          sulfur-containing amino acid + 5
                                          trovafloxacin 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.